Post‐transcriptional regulation of PIAS3 expression by miR‐18a in malignant mesothelioma

by Tian He, Karen McColl, Nneha Sakre, Yanwen Chen, Gary Wildey, Afshin Dowlati
Published 2018-12-01

Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data

by Qing Ye, Joseph Putila, Rebecca Raese, Chunlin Dong, Yong Qian, Afshin Dowlati, Nancy Lan Guo
Published 2021-07-01

Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer.

by Gary Wildey, Yanwen Chen, Ian Lent, Lindsay Stetson, John Pink, Jill S Barnholtz-Sloan, Afshin Dowlati
Published 2014-01-01

A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated...

by Kylie H. Kang, Jimmy T. Efird, Tarun K. Podder, Yuxia Zhang, Afshin Dowlati, Mitchell Machtay, Charulata Jindal, Tithi Biswas
Published 2021-03-01

A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials

by Michelle Treasure, Barbara Daly, Shufen Cao, Pingfu Fu, Augustine Hong, Elizabeth Weinstein, Jessica Surdam, Neal J. Meropol, Afshin Dowlati
Published 2021-07-01

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer

by Priyanka Bhateja, Michelle Chiu, Gary Wildey, Mary Beth Lipka, Pingfu Fu, Michael Chiu Lee Yang, Fatemeh Ardeshir‐Larijani, Neelesh Sharma, Afshin Dowlati
Published 2019-04-01

Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer

by Tian He, Gary Wildey, Karen McColl, Alyssa Savadelis, Kyle Spainhower, Cassidy McColl, Adam Kresak, Aik Choon Tan, Michael Yang, Ata Abbas, Afshin Dowlati
Published 2021-01-01

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries

by Avirup Guha, Prantesh Jain, Michael G. Fradley, Daniel Lenihan, Jahir M. Gutierrez, Chhavi Jain, Marcos deLima, Jill S. Barnholtz‐Sloan, Guilherme H. Oliveira, Afshin Dowlati, Sadeer Al‐Kindi
Published 2021-06-01

A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer

by Nancy Lan Guo, Afshin Dowlati, Rebecca A. Raese, Chunlin Dong, Guoan Chen, David G. Beer, Justine Shaffer, Salvi Singh, Ujala Bokhary, Lin Liu, John Howington, Thomas Hensing, Yong Qian
Published 2018-06-01

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

by Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens, Hope S. Rugo
Published 2019-06-01

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

by Jonathan W. Goldman, Minal Barve, Jyoti D. Patel, Antoinette Wozniak, Afshin Dowlati, Alexander Starodub, Taofeek K. Owonikoko, William Edenfield, Scott A. Laurie, Daniel Da Costa, Satwant Lally, Martina Koch, Matthew P. Kosloski, David Hoffman, Grace K. Dy
Published 2021-03-01

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA

by Justin D. Finkle, Hala Boulos, Terri M. Driessen, Christine Lo, Richard A. Blidner, Ashraf Hafez, Aly A. Khan, Ariane Lozac’hmeur, Kelly E. McKinnon, Jason Perera, Wei Zhu, Afshin Dowlati, Kevin P. White, Robert Tell, Nike Beaubier
Published 2021-07-01

374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors

by Afshin Dowlati, Andrea Bullock, Susanna Ulahannan, Manish Patel, Shubham Pant, Amita Patnaik, Marsha Crochiere, Devalingam Mahalingam, Wael Harb, Haider Mahdi, Manmeet Ahluwalia, Patrick Wen, Mary Mulcahy, Robert Guttendorf, Lou Vaickus, Suming Wang, Melanie Vincent, Michael Cieslewicz, Jing Watnick
Published 2020-11-01

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

by Michael E Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace L Akerley, Afshin Dowlati, Benjamin C Creelan, James K Hicks, Paul J Hesketh, Karen L Kelly, Jonathan W Riess, Vincent A Miller, Philip J Stephens, Garrett M Frampton, Siraj Ali, Jeffrey P Gregg, Lee A Albacker
Published 2018-01-01